T7005

Ulixertinib (VRT752271) (BVD-523, VRT752271) is an effective and reversible ERK1/ERK2 inhibitor. The IC50 of Ulixertinib is less than 0.3 nM for ERK2.

PQR514 is a potent PI3K inhibitor with anticancer activity and inhibits cancer cell proliferation.

Boditrectinib, a potent tyrosine kinase inhibitor, functions as an antineoplastic agent and is valuable in researching cancer, inflammation, neurodegenerative diseases, and certain infectious diseases.

Ulixertinib hydrochloride (Ulixertinib HCl) is an orally available, selective and potent ERK1/2 inhibitor with anticancer and antitumor activity that inhibits the NB cell cycle and promotes apoptosis, and may be used in the study of solid tumors.